Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04158700
Title A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

transitional cell carcinoma

hepatocellular carcinoma

lung non-small cell carcinoma

Therapies

LY3200882 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | FRA | ESP


No variant requirements are available.